Francis Lévi

18PUBLICATIONS
60CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Environmental epidemiologyCardiology (incl. cardiovascular diseases)Sexualities
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|May 04, 2026
Impact of Neoadjuvant Chemotherapy Administration Time of Day on Pathological Response in Patients with Early Triple-Negative Breast Cancer.

|Feb 02, 2026
Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.

Zhe Huang, Liang Zeng, Zhaohui Ruan

|Dec 15, 2025
Timing of Immunotherapy in Practice: Feasibility and Impact of Morning Checkpoint Inhibitor Administration.

Pasquale F Innominato, Thierry Landré, Abdoulaye Karaboué

|Aug 24, 2025
Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD Trial.

Enora Laas, Anne-Sophie Hamy, Thomas Bachelot

|Jun 04, 2024
Why does circadian timing of administration matter for immune checkpoint inhibitors' efficacy?

Abdoulaye Karaboué, Pasquale F Innominato, Nicholas I Wreglesworth

|Aug 12, 2023
International e-Delphi Consensus Recommendations for the Assessment and Diagnosis of Circadian rest-Activity Rhythm Disorders (CARDs) in Patients with Cancer.

Craig Gouldthorpe, Sonia Ancoli-Israel, Elizabeth Cash

Pageof 3

Frequent Collaborators

7 joint publications

Pasquale Innominato

5 joint publications

Abdoulaye Karaboué

3 joint publications

Yongchang Zhang

3 joint publications

Sandra Komarzynski